FDAnews Drug Daily Bulletin
May 12, 2005 | Vol. 2 No. 94
Cellerant Therapeutics Raises $16 Million
Cellerant Therapeutics Inc. announced that it has raised $16 million in a series B financing led by Novel Bioventures. Participants in this round included George Rathmann and CX Venture Group. Allen & Company and MPM Capital were among the Series A stockholders who also invested in this financing. "Cellerant represents one of the strongest and most impressive platforms and management teams for commercializing stem cell products," said Han Chiu, M.D., Managing Director of Novel Bioventures.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.